Moreover, we confirmed that CANX can activate the MEK/ERK/BNIP3 pathway to achieve resistance to TMZ chemotherapy through mitophagy, indicating that CANX is a potential therapeutic target for GBM. This evidence concerns the gene MAP2K7 and glioblastoma.